Onoda_2022_Case.Rep.Anesthesiol_2022_9268454

Reference

Title : A New Anesthetic, Remimazolam, Is Useful in the Management of Anesthesia in Patients with Liver Cirrhosis - Onoda_2022_Case.Rep.Anesthesiol_2022_9268454
Author(s) : Onoda A , Suzuki Y
Ref : Case Rep Anesthesiol , 2022 :9268454 , 2022
Abstract :

BACKGROUND: Management of general anesthesia in patients with liver cirrhosis is challenging because it is difficult to maintain the circulation and concentration of anesthetics within a safe range. Unlike many other anesthetics, which are metabolized by cytochrome P450 enzymes, remimazolam is metabolized by carboxylesterase. In a liver cirrhosis model, cytochrome P450 activity is suppressed by approximately 30%; however, carboxylesterase activity is maintained at approximately 60%. Also, remimazolam is less likely to inhibit circulation. A 77-year-old woman was scheduled to undergo laparoscopic cholecystectomy. The patient was diagnosed with Child-Pugh B liver cirrhosis due to type C viral hepatitis. General anesthesia with remimazolam stabilized the intraoperative circulation and resulted in rapid postoperative awakening. CONCLUSION: We report a case in which a patient with Child-Pugh B cirrhosis was safely managed under general anesthesia using remimazolam during laparoscopic cholecystectomy.

PubMedSearch : Onoda_2022_Case.Rep.Anesthesiol_2022_9268454
PubMedID: 35578641

Related information

Substrate Remimazolam

Citations formats

Onoda A, Suzuki Y (2022)
A New Anesthetic, Remimazolam, Is Useful in the Management of Anesthesia in Patients with Liver Cirrhosis
Case Rep Anesthesiol 2022 :9268454

Onoda A, Suzuki Y (2022)
Case Rep Anesthesiol 2022 :9268454